Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations

Molecular Neurodegeneration

Volumn 10, Issue 1, 2015, Pages

  Bettens, Karolien ^a,b   Vermeulen, Steven ^a,b   Van Cauwenberghe, Caroline ^a,b   Heeman, Bavo ^a,b   Asselbergh, Bob ^a,b   Robberecht, Caroline ^a,b   Engelborghs, Sebastiaan ^b,c   Vandenbulcke, Mathieu ^d   Vandenberghe, Rik ^d   De Deyn, Peter Paul ^b,c,e   Cruts, Marc ^a,b   Van Broeckhoven, Christine ^a,b   Sleegers, Kristel ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Hospital Network Antwerp Middelheim and Hoge Beuken   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Alzheimer's disease; Cell secretion; Clusterin; Golgi; Mutations; Rare variant; chain

Indexed keywords

CLUSTERIN; CLU PROTEIN, HUMAN; CYSTINE; HYBRID PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BELGIAN; BETA CHAIN; CLU GENE; COMPUTER MODEL; CONTROLLED STUDY; EMBRYO; ENDOPLASMIC RETICULUM; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GOLGI COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN TRANSPORT; AMINO ACID SUBSTITUTION; BELGIUM; CHEMISTRY; DIMERIZATION; EXON; FRAMESHIFT MUTATION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; PATHOPHYSIOLOGY; PROTEIN CONFORMATION; SECRETION (PROCESS); TRANSPORT AT THE CELLULAR LEVEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; BELGIUM; BIOLOGICAL TRANSPORT; CLUSTERIN; CYSTINE; DIMERIZATION; ENDOPLASMIC RETICULUM; EXONS; FEMALE; FRAMESHIFT MUTATION; GOLGI APPARATUS; HEK293 CELLS; HELA CELLS; HUMANS; MALE; MUTATION, MISSENSE; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 84988662285     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-015-0024-9     Document Type: Article

References (29)

1. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088-93.
2. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094-9.
3. Bettens K, Brouwers N, Engelborghs S, Lambert J-C, Rogaeva E, Vandenberghe R, et al. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener. 2012;7:3.
4. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812-4.
5. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248-9.
6. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev. 2009;61:89-104.
7. Pasinetti GM, Johnson SA, Oda T, Rozovsky I, Finch CE. Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J Comp Neurol. 1994;339:387-400.
8. Saura J, Petegnief V, Wu X, Liang Y, Paul SM. Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. J Neurochem. 2003;85:1455-67.
9. Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD, et al. Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem. 2005;280:14212-21.
10. Ling IF, Bhongsatiern J, Simpson JF, Fardo DW, Estus S. Genetics of clusterin isoform expression and Alzheimer's disease risk. PLoS One. 2012;7, e33923.
11. Kimura K, Yamamoto M. Modification of the alternative splicing process of testosterone-repressed prostate message-2 (TRPM-2) gene by protein synthesis inhibitors and heat shock treatment. Biochim Biophys Acta. 1996;1307:83-8.
12. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem. 2003;278:11590-600.
13. Prochnow H, Gollan R, Rohne P, Hassemer M, Koch-Brandt C, Baiersdorfer M. Non-secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-kappaB signaling pathway. PLoS One. 2013;8, e75303.
14. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45:1452-8.
15. Narayan P, Orte A, Clarke RW, Bolognesi B, Hook S, Ganzinger KA, et al. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-beta(1-40) peptide. Nat Struct Mol Biol. 2011;19:79-83.
16. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol. 1995;27:633-45.
17. Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Guntert A, et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage. 2012;59:212-7.
18. Dabbs RA, Wilson MR. Expression and purification of chaperone-active recombinant clusterin. PLoS One. 2014;9, e86989.
19. Zhou Y, Hayashi I, Wong J, Tugusheva K, Renger JJ, Zerbinatti C. Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein tau in Alzheimer's disease. PLoS One. 2014;9, e103187.
20. Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, et al. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatry. 2003;74:1148-51.
21. Engelborghs S, Dermaut B, Marien P, Symons A, Vloeberghs E, Maertens K, et al. Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol Aging. 2006;27:285-92.
22. Bettens K, Brouwers N, van Miegroet H, Gil A, Engelborghs S, De Deyn PP, et al. Follow-Up study of susceptibility loci for Alzheimer's disease and onset Age identified by genome-wide association. J Alzheimers Dis. 2009;19:1169-75.
23. Reumers J, De Rijk P, Zhao H, Liekens A, Smeets D, Cleary J, et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol. 2011.
24. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589-95.
25. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. Genome Res. 2010;20:1297-303.
26. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061-73.
27. Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, Orozco M. PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics. 2005;21:3176-8.
28. Salmon P, Trono D. Production and titration of lentiviral vectors. Curr Protoc Neurosci. 2006;4:Unit 4.21.
29. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-5.